Innovation Pharmaceuticals Inc (IPIX)

[shazamm]

Great find Dr B….

What Do We Have: Clinical Trials with Antiviral HDP, Peptoids, and Synthetic Peptides

The emerging novel viruses have prompted the research for new antiviral therapies, putting into the spotlight HDPs because of their antiviral and immunomodulatory features. Although thousands of HDPs have been reported, only a few of them have reached clinical trials, and even fewer have been approved for clinical practice.

Similarly, brilacidin is peptidomimetic, with non-peptidic scaffolds and side chains, which has structural and biological properties similar to HDPs, it has been tested in phase II for skin acute bacterial infection, ulcerative proctitis, and viral infections. Recently, this peptidomimetic has been evaluated in a human lung cell line and Vero cells. These results suggest that SARS-CoV-2 inhibition in these cell culture models is likely to be a result of the impact of brilacidin on viral entry and its disruption of viral integrity (Bakovic et al. 2021).